A multi-locus predictiveness curve and its summary assessment for genetic risk prediction

Changshuai Wei^a*, Ming Li^b, Yalu Wen^c, Chengyin Ye^d and Qing Lu^e*

With the advance of high-throughput genotyping and sequencing technologies, it becomes feasible to comprehensive evaluate the role of massive genetic predictors in disease prediction. There exists, therefore, a critical need for developing appropriate statistical measurements to access the combined effects of these genetic variants in disease prediction. Predictiveness curve is commonly used as a graphical tool to measure the predictive ability of a risk prediction model on a single continuous biomarker. Yet, for most complex diseases, risk prediciton models are formed on multiple genetic variants. We therefore propose a multi-marker predictiveness curve and provide a non-parametric method to construct the curve for case-control studies. We further introduce a global predictiveness U and a partial predictiveness U to summarize prediction curve across the whole population and sub-population of clinical interest, respectively. We also demonstrate the connections of predictiveness U to other three summary indices: R square, Total Gain, and Average Entropy, and showed that Predictiveness U outperformed the other three indexes in terms of unbiasedness and robustness. Moreover, we simulated a series of rare-variants disease model, found partial predictiveness Curve and predictiveness U performed better than global predictiveness U. Finally, we conducted a real data analysis, using predictiveness curve and predictiveness U to evaluate a risk prediction model for Nicotine Dependence.

Keywords: High-dimensional Data; Non-parametric Statistic; Nicotine Dependence

Introduction

Genome-wide association studies have discovered thousands of disease-susceptibility loci for complex diseases. Although each locus has only a moderate or low effect on diseases, jointly they can significantly influence the disease risk. Risk predictive models capitalizing on the combined information of newly identified genetic variants and existing risk predictors thus hold great promise for individualized disease prediction and prevention. For this reason, studies to assess the combined role of newly genetic loci in early disease prediction represent high priority research projects, as manifested in the multiple risk predictive modeling studies now underway. The yield from these ongoing risk prediction studies can be enhanced by adopting appropriate methods and measurements that comprehensively evaluate risks on the population scale.

The receiver operating characteristic (ROC) curve have been a very popular tool to evaluate clinical validity of a risk prediction model. It comprises of all possible pairs of senesitivty and specificity, and there is a global measure of a model's classification accucy. Yet, the ROC curve does not assess the clinical utility of the model. To access the prediction performance of a risk model and its clinical utility on population level, Pepe et al [1] propose a graphical tool,

^a Department of Biostatistics and Epidemiology, University of North Texas Health Science Center.

^b Department of Epidemiology and Biostatistics, Indiana University Bloomington.

^c Department of Statistics, University of Auckland

^d School of Medicine, Hangzhou Normal University.

^e Department of Epidemiology and Biostatistics, Michigan State University.

^{*} Correspondence to: Qing Lu, Department of Epidemiology and Biostatistics, Michigan State University. E-mail: qlu@epi.msu.edu.

Changshuai Wei, Department of Biostatistics and Epidemiology, University of North Texas Health Science Center. E-mail: changshuai.wei@unthsc.edu This is the author's manuscript of a paper published in https://doi.org/10.1177/0962280218819202

predictiveness curve. Predictiveness curve is constructed by plotting each individual's predicted risks versus its quantile, or in another word, the transpose of the cumulative distribution function of risk distribution. Thus, the predictiveness curve displays the information of the risk distribution on population level. Huang et al [2, 3]studies the asymptotic property of the predictiveness curve and developed methods for estimating the predictiveness curve of single continuous biomarker for case-control design. Nevertheless, complex diseases are commonly manifested by multiple risk predictors, which call the need of predictiveness curve for multiple risk predictors.

Besides graphical evaluation, a summary index for predictiveness curve is necessary for numerically evaluation of prediction models, especially when the number of models for comparison is large. Several summary indexes have been proposed for predictiveness curve of a single continuous marker, for instance, the variance of the predicted risks. Intuitively, a large variance of predicted risk means the marker assigned different risks to subjects, indicating good prediction performance of the marker. If we divide the variance by the variance of a perfect predictor, we obtain a R-square statistic[4]. Considering R square is not suitable for a binary response[5], two other summary indexes were proposed: Average Entropy and Total Gain.[2, 6, 7] Average Entropy was defined by calculating the reduction in maximum log-likelihood, and can be considered a generalized R-square statistic. Total Gain was proposed by Bura et al[7] to summarize the binary regression quantile plot. Total Gain can be also considered as a generalized R-square statistic, by replacing the squared risk difference with the absolute value of risk difference. The existing summary indexes, however, were developed for single continuous predictor, where there is a natural underlying order. For multiple predictors, the order is yet to be defined and summary indexes without considering ordering information may not have optimum performance.

U statistic[8] is well known for its flexibility and robustness, and have been recently applied to genetic association study by incorperating ordering information of multiple genetic variants[9, 10]. U statistic, in particular, Mann-Whiteney U, has been shown to be an optimum summary index for ROC curve[11]. Thus we proposed a predictiveness U to summarize the predictiveness curve for multiple predictors with consideration of ordering information. In the following sections, we first developed a predictiveness curve and predictiveness U for multiple predictors. We then showed their connections with ROC curve and Lorenze curve. We provided asymptotic results for predictiveness U for efficient inference. At last, we performed simulations to compare predictiveness U with other summary indexes followed with a real data application on Nicotine Dependence.

Method

Multimarker predictiveness curve

Assume we have an random variable \mathcal{G} , which represents multiple genetic variants. Let F(g) be the cumulative distribution function (c.d.f) of \mathcal{G} , such that $F(g) = P(\mathcal{G} \leq g)$. Then, the predictiveness curve can then be defined as a function that maps genetic quantile q = F(g) to predicted risk r(q),

$$r: q \to r(q).$$

It is crucial to order the genetic variants g, so as to have meaningful definition of $F(g) = P(\mathcal{G} \leq g)$. Here, we assume that the order of g is concordant with the order of predicted genetic risk r, so that the predictiveness curve is an monotone increasing curve. In fact, under the monotone increasing assumption, predictiveness curve is just the inverse cumulative distribution function of predicted genetic risk $r = F_r^{-1}(q)$, where F_r is c.d.f of r.

Because there is natural order underlying a single continuous marker, it is convenient to obtain a monotonically increasing predictiveness curve for the single marker. However, for multiple markers, especially the categorical genetic variants, the underlying order is unknown. Nonetheless, we perform transformation on the categorical multi-locus genotypes, making the corresponding predictiveness curve monotonically increasing with the transformed genotype. To illustrate, we assume there are m genetic markers in the risk prediction model, which comprise of G_m multi-locus genotypes. Let r_i ($r_i = P(D|g_i)$) and p_i ($p_i = P(g_i)$) denote the predicted risk and the population proportion of the multi-locus genotype g_i ($1 \le i \le G_m$). Given a binary disease phenotype with the disease prevalence of ρ , we can calculate r_i and p_i :

$$r_i = \frac{P(g_i|D)\rho}{P(g_i|D)\rho + P(g_i|\bar{D})(1-\rho)},$$
$$p_i = P(g_i|D)\rho + P(g_i|\bar{D})(1-\rho),$$

where $P(g_i|D)$ and $P(g_i|\overline{D})$ denote proportion of g_i carrier in diseased sub-population and non-diseased sub-population, respectively. We ordered the multi-locus genotype from lowest risk to highest risk (so that $r_i > r_j$ for i > j) and plotted the ordered risk (r_i) against the risk quantile q_i ($q_i = \sum_{j=0}^{i} p_i$), whereby we obtain a multi-marker predictiveness curve.

For case-control data, $P(g_i|D)$ can be estimated as $\hat{P}(g_i|D) = \frac{n_{D,g_i}}{n_D}$, where n_D is the number of cases, and n_{D,g_i} is the number of g_i carrier in cases. $\hat{P}(g_i|\bar{D})$ can be estimated in a similar way. The disease prevalence ρ can be obtained from previous literature or another independent cohort study. With $\hat{P}(g_i|D)$, $\hat{P}(g_i|\bar{D})$ and ρ , we can obtain \hat{r}_i , \hat{p}_i and thus an estimator of the predictiveness curve.

Predictiveness U

Various single marker summary indexes have been proposed to summarize predictiveness curve. Most of them, however, are not approporate for predictiveness curve built on multiple markers. To measures the prediction performance of a set of markers on the population level, we propose a predictiveness U. Given the predictiveness curve, we can calculated the predictiveness U by,

$$U = 2\sum_{i>j} p_i p_j \psi(r_i, r_j),$$

where the kernel $\psi(r_i, r_j)$ measures the difference of disease impact between g_i carrier and g_j carrier, $p_i p_j$ weights the impact on the population level. Different forms of $\psi(r_i, r_j)$ can be chosen so as to incorporate cost associated with disease risks. Here in this paper, we use risk difference $\psi(r_i, r_j) = r_i - r_j$.

The above definition can be generalized to the general predictiveness curve, $r: q \to r(q)$, where we define the predictiveness U as

$$U = 2 \int_0^1 \int_0^y \psi(r(y), r(x)) dx dy.$$

When $\psi(r_i, r_j) = r_i - r_j$, the predictiveness U can be written as $U = 2 \int_0^1 \int_0^y (r(y) - r(x)) dx dy$. Furthermore, we can standardize predictiveness U by dividing it by its maximum value (i.e., perfect prediction). For risk difference kernel, the standardized predictiveness U can be calculated by $U^{st} = [\int_0^1 \int_0^y (r(y) - r(x)) dx dy] / [\rho(1 - \rho)]$, which scale from 0 to 1.

In a population of size N, suppose genotype g_i has N_i carrier and is associated with disease risk r_i . With $p_i = N_i/N$, the Predictiveness U can be written as a one sample U-statistic,

$$U = \frac{\sum_{i>j} N_i N_j \psi(r_i, r_j)}{\frac{N(N-1)}{2}}$$

Using Hoeffding projection, we can calculate the population variance of predictiveness U by:

$$var(U) = \frac{4}{N}var(E(\psi(r_1, r_2)|r_1)) = \frac{4}{N}\sum_{i=1}^{G_m} \frac{N_i}{N} (\sum_{j=1}^{G_m} \frac{N_j}{N}\psi(r_i, r_j) - U)^2.$$

In clinical application, our interest may lie in a sub-population with specific range of risk quantile $q \in (q_0, q_1)$. We can define a partial predictiveness U, $U_{pt} = 2 \int_{q_0}^{q_1} \int_{q_0}^{y} \psi(r(y), r(x)) dx dy$, to evaluate the prediction performance of a model on the sub-population. With the given risk difference kernel, the partial predictiveness U becomes,

$$U_{pt} = 2 \int_{q_0}^{q_1} \int_{q_0}^{y} (r(y) - r(x)) dx dy.$$

We can also standardize partial predictiveness U to make it ranges 0 to 1, i.e., $U_{pt}^{st} = [\int_{q_0}^{q_1} \int_{q_0}^y (r(y) - r(x)) dx dy] / [\rho_{pt}(1 - \rho_{pt})]$, where $\rho_{pt} = \int_{q_0}^{q_1} r(x) dx$. The calculation of the population variance for partial predictiveness U is similar as that of global predictiveness U by considering constraint on the selected range of risk quantile.

Connection with ROC curve and Lorenze Curve

In this subsection, we show the connection of predictiveness curve and ROC curve and Lorenze Curve (Figure 1). For simplicity, we limit our discussion to predictiveness U with risk difference kernel $\psi(r_1, r_2) = r_1 - r_2$.

The ROC curve has been a popular visualization method to evaluate the classification accuracy of a genetic risk prediction model[11]. It is formed by plotting the *sensitivity* against 1 - specificity at various thresholds. The area under the ROC curve AUC_R is often used as a summary index for classification accuracy of the prediction model, where higher value of AUC_R represents higher classification accuracy. With a threshold genotype g, we can have the following decision rule for the predicted disease status Y_g ,

$$Y_g = \begin{cases} 1, & \mathcal{G} > g, \\ 0, & \mathcal{G} \le g. \end{cases}$$



Figure 1. Predictiveness curve, ROC curve and Lorenz curve

The ROC curve can then be formed by plotting sensiticity (i.e., $P(Y_g = 1|D)$ against 1 - specificity (i.e., $1 - P(Y_g = 0|\overline{D})$) at various threshold g. In particular, the ROC curve is represented by a map: $f: t \to f(t)$, where $t_g = 1 - P(Y_g = 0|\overline{D})$ and $f(t_g) = P(Y_g = 1|D)$. Let $F_D(g)$, and $F_{\overline{D}}(g)$ denote the c.d.f of ordered genotype \mathcal{G} in the diseased sub-population and non-diseased sub-population. With decision rule on \mathcal{G} , the ROC curve can be represented as,

$$t_g = 1 - F_{\bar{D}}(g),$$

 $f(t_g) = 1 - F_D(g).$

Meanwhile, the predictiveness curve can be written as (Appendix A),

$$q_g = \rho F_D(g) + (1 - \rho) F_{\bar{D}}(g),$$

$$r(q_g) = \frac{F'_D(g)\rho}{F'_D(g)\rho + F'_{\bar{D}}(g)(1 - \rho)}.$$

Thus both ROC curve and predictiveness curve can be written as function of $F_D(g)$ and $F_{\overline{D}}(g)$. Further, we can show (Appendix A) that AUC_R and predictiveness U have the following relationship,

$$U = 2\rho(1-\rho)(2AUC_R - 1).$$

Since the diagnal line for ROC curve represents the discriminative ability of a non-informative marker, the area between ROC curve and diagnal line ($\Delta AUC_R = AUC_R - 0.5$) represents the net classification improvement of a predictive marker. In other words, the predictiveness U is just the net classification improvement of the ROC curve multiplied by a factor related to disease prevalence, i.e., $U = 4\rho(1 - \rho)\Delta AUC_R$.

Lorenz curve was originally invented to measure the income inequality. Nonetheless, We can also use Lorenz curve to measure risk inequality in the population. Each point on the Lorenz curve maps the risk quantile q to the percentage of cumulative risk $h(q) = \frac{\int_0^q r(u)du}{\rho}$. The diagonal line in Lorenz curve represents the scenario of no risk inequality, where all the individuals in the population have the same risk. In a real population, the Lorenz curve should be an convex curve. The further away the Lorenz curve is from the diagonal line, the more risk inequality the population exhibits. Denote the area under the Lorenze curve as $AUC_L = \int_0^1 h(u)du$. The degree of risk inequality can be measured by the area between the diagonal line and the Lorenze curve, $\Delta AUC_L = 0.5 - AUC_L$. We can show (Appendix B) that AUC_L and predictiveness U have the following relationship

$$U = 2\rho(0.5 - AUC_L)$$

which means that predictiveness U can be represented as the degree of risk inequality multiplied by a factor related to disease prevalence, i.e., $U = 2\rho \Delta AUC_L$.

Estimation and inference

We can apply an existing prediction model to an independent dataset to evaluate the performance of a set of selected markers. In particular, we first estimate the predicted risk for each multi-locus genotype in the testing dataset. Based on the order of the multi-locus genotypes from the training dataset and newly estimated predicted riks, we can obtain the predictiveness curve, which is not necessary monotonically increasing. A new preidctiveness U can be calculated to evaluate the prediction performance.

For case-control study, we need to first estimate $\hat{P}(g_i|D)$ and $\hat{P}(g_i|\bar{D})$ from cases and controls seprately. Then, using ρ estimated from another cohort study, we can obtain \hat{r}_i, \hat{p}_i , and thus the predictiveness U, $\hat{U} = 2 \sum_{i>j} \hat{p}_i \hat{p}_j (\hat{r}_i - \hat{r}_j)$. We can use permutation method to perform hypothesis test and boostrap method to construct confidence interval for predictiveness U. Here, we also derive the asymptotic variance of predictiveness U. For case-control data, the predictiveness U can be written as a two sample U statistic (Appendix C),

$$\hat{U} = 2\rho(1-\rho)\frac{1}{n_D n_{\bar{D}}} \sum_{s=1}^{n_D} \sum_{t=1}^{n_{\bar{D}}} \phi(g_s, g_t),$$

where g_s is the genotype of s-th subject in cases, g_t is the genotype of t-th subject in controls and the kernel $\phi(g_s, g_t)$ is defined as,

$$\phi(g_s, g_t) = \begin{cases} 1, & g_s > g_t \\ 0, & g_s = g_t \\ -1, & g_s < g_t \end{cases}$$

The asymptotic variance of predictiveness U can be calculated by (Appendix C),

$$\begin{aligned} var(\hat{U}) &= 4\rho^2 (1-\rho)^2 \left[\frac{1}{n_D (n_D - 1)} \sum_{s=1}^{n_D} \left(\frac{1}{n_{\bar{D}}} \sum_{t=1}^{n_{\bar{D}}} \phi(g_s, g_t) - \hat{U}\right)^2 \\ &+ \frac{1}{n_{\bar{D}} (n_{\bar{D}} - 1)} \sum_{t=1}^{n_{\bar{D}}} \left(\frac{1}{n_D} \sum_{s=1}^{n_D} \phi(g_s, g_t) - \hat{U}\right)^2 \right]. \end{aligned}$$

Result

We conducted simulation studies and real data analysis to evaluate the performance of predictiveness U. In particular, we first compared the performance of standardized global predictiveness U with three other indexes: Average Entropy ($AE = \int r(x) logr(x) + (1 - r(x)) log(1 - r(x)) dx$), R square ($R = \int (r(x) - \rho)^2 dx$) and Total Gain ($TG = \int |r(x) - \rho| dx$). To evaluate the performance of predictiveness U on a small group of individuals carrying rare variants, we compared the standardized global predictiveness U with the standardized partial predictiveness U. Finally, we performed a real data application and built a Nicotine Dependence risk prediction model based on 37 candidate SNPs and 7 environmental risk factors.

Simulation I

We simulated a population with 1 million people with the disease prevalence fixed at 0.016. The simulated disease status is influenced by the combining effects of 4 SNPs (minor allele frequency > 0.01), whereby SNPs were assigned with various marginal effects (additive, dominance or recessive model) as well as interaction effects among them. We simulated 4 disease models, by gradually increasing the heritability of the disease (Figure 2). We evaluated the performance of 4 different summary indexes on 1000 case-control data sets sampled from the simulated population.

The mean and standard deviations for each index were calculated from 1000 data replicates to measure the accuracy and variation of the estimation. However, since the scale of the indices were different, it was not convenient to compare their performance based on mean and standard deviations. Therefore, we calculate % of Bias and % of Coverage to measure the accuracy and variation of the estimator. % of Bias is calculated by taking the ratio of the bias and true value. % of Coverage is calculated by counting the percentage of the times that 95% CI covers the true value, whereby the confidence intervals were calculated by using bootstrap sampling method.

The simulation results are summarized in Table 1. Overall, the Bias of predictiveness U is minimal across the 4 summary indices, except that under high heritability model, TG has comparative bias as predictiveness U. For % of coverage, we found similar trend. As the heritability increase, TG, R and AE gain limited improvement, while, predictiveness U consistently obtained the high coverage rate.

Predictiveness U takes the order of multi-locus genotypes into consideration, and therefore can handle the nonmonotone of the predictiveness curve when applying model to the testing data. This can partially explain the advantage of Predictiveness U over the other three indices. To make the comparison more "fair", we use isotonic regression to refit



Figure 2. Predictiveness Curves for Simulation I

Table 1. Comparison of predictiveness U with three other prediction summary indices

Heritability		U	R	TG	AE
0.02	True value	0.199	0.00223	0.142	0.0125
	Mean	0.194	0.00666	0.175	0.0225
	SD	0.0173	0.00233	0.0126	0.00308
	% of Bias	2.51	198	22.9	79.9
	% of Coverage	93.4	0	0	0
0.05	True value	0.312	0.00611	0.225	0.0317
	Mean	0.305	0.0128	0.248	0.0427
	SD	0.0178	0.00373	0.0137	0.00483
	% of Bias	2.26	109	10.4	34.8
	% of Coverage	90.3	0	8.8	0
0.1	True value	0.437	0.0145	0.328	0.0654
	Mean	0.436	0.0244	0.346	0.0791
	SD	0.0161	0.00553	0.0138	0.00666
	% of Bias	0.14	67.8	5.31	21
	% of Coverage	92.6	0.2	34.5	11
0.2	True value	0.599	0.041	0.475	0.138
	Mean	0.596	0.0576	0.476	0.153
	SD	0.0138	0.0108	0.0138	0.01
	% of Bias	0.464	40.5	0.173	11.2
	% of Coverage	92.8	0.066	86.2	11.5

the predictiveness curve before summarizing the curve. By doing so, we force the predictiveness curve to be monotone increasing in testing data. The new simulation results are summarized in Table 2. We found that predictiveness U still has the minimal bias across the 4 indices. In terms of coverage, predictiveness U is comparative with TG, and much higher than R and AE.

Heritability		U	R	TG	AE
0.02	True value	0.199	0.00224	0.142	0.0125
	Mean	0.202	0.00302	0.146	0.0141
	SD	0.0168	0.00103	0.014	0.00237
	% of Bias	1.39	35	2.29	12.9
	% of Coverage	92.3	60.8	90.9	73.8
0.05	True value	0.312	0.00612	0.225	0.0317
	Mean	0.312	0.00795	0.228	0.0337
	SD	0.0175	0.00227	0.0149	0.00415
	% of Bias	0.006	30	1.39	6.42
	% of Coverage	91.9	55.1	90.8	78.7
0.1	True value	0.437	0.0145	0.328	0.0654
	Mean	0.442	0.0179	0.334	0.0694
	SD	0.0159	0.00387	0.0146	0.00597
	% of Bias	1.29	23.2	1.75	6.13
	% of Coverage	88.1	57.6	90.1	74.2
0.2	True value	0.599	0.041	0.475	0.138
	Mean	0.601	0.0476	0.471	0.142
	SD	0.0136	0.00864	0.0142	0.00906
	% of Bias	0.399	15.9	0.759	3.25
	% of Coverage	91.1	67.9	93.2	81.3

Table 2. Comparison of predictiveness U with three other prediction summary indices under monotonic restriction

Figure 3. Predictiveness Curve for Simulation II



Simulation II

Clinical interest sometimes focuses on a specific risk quantile rather than the whole population. In such a case, partial predictiveness U is more useful than global predictiveness U. Here, we simulated three disease models, each influenced by 2 common variants and 2 rare variants. We fixed the effects of the common variants at moderate level while varying the effects of rare variants from moderate level to high level (Figure 3). From Figure 3 we observed that the rare variants mainly affected the high risk subpopulation. We use partial predictiveness U to summarize the predictiveness curve on the highest 10% risk quantile. Similarly as in simulation I, we investigated the performance of the two indices, using 1000 sampled data sets from simulated population under each disease model. The simulation results are summarized in Table 3. We found that, as the effect size of rare variants increases, both global predictiveness U and partial predictiveness U have better prediction. Partial predictiveness U outperformed global predictiveness U in terms of both % of Bias and % of Coverage. This is probably due to the fact that partial predictiveness U focuses on the high risk subpopulation, and for the three rare-variants-dominated disease models, the high risk quantile summarized majority of the information, which is in favor of partial predictiveness U.

	moderate RR _{rare}		moderate high RR _{rare}		high RR _{rare}	
	U	U_{pt}	U	U_{pt}	U	U_{pt}
True value	0.0298	0.103	0.0432	0.243	0.0527	0.312
Mean	0.0201	0.13	0.0325	0.251	0.0422	0.316
SD	0.0147	0.061	0.0142	0.0563	0.0147	0.0537
%Bias	32.6	26.4	24.7	3.3	20	1.38
%Coverage	32.3	58.8	64.8	98.4	83.3	100

	Table 3. Com	parison of	predictiveness	U and	partial	predictiveness	U
--	--------------	------------	----------------	-------	---------	----------------	---

Application to Nicotine Dependence

Tobacco-attributable morbidity and mortality represents a remarkable 21st century global burden of disease. In US population, the lifetime prevalence of nicotine dependence is about 24%. Associated with cigarette smoking, it becomes a leading risk factor for lung cancer. Both gene and environment play an important role in nicotine dependence. Twin and family studies estimated that the heritability of nicotine dependence to be around 59%.[12] Despite the high heritability, the currently-discovered SNPs has limited value in predicting Nicotine Dependence. In this application, we combined genetic variants and environmental determinants to build a prediction model for Nicotine dependence, using a GWAS dataset from the study of Addiction: Genetics and Environment (SAGE).

Two independent samples in SAGE: Family Study of Cocaine dependence (FSCD) and Collaborative Genetic Study of Nicotine Dependence (COGEND), were used as training data and validation data respectively. DSM-IV defined Nicotine Dependence was set as binary outcome for analysis. In particular, there are 486 cases and 684 controls in FSCD and 696 cases and 708 controls in COGEND. From previous literature, we selected 37 SNPs that were potentially associated with Nicotine dependence. 7 non-genetic risk factors, including sex, age, education, income, and 3 types of trauma experience were also included in the analysis.

To determine a parsimonious model, we applied a forward selection algorithm[13] with a build-in cross-validation process to the 44 predictors on the training data. The algorithm selected 3 risk predictors: income, physical trauma and a genetic variant, rs2656073, into the final risk prediction model. We then visualized the prediction model by a predictiveness curve. The curve showed moderate prediction accuracy, with a global predictiveness U of 0.160. We further evaluated the performance of the prediction model using the COGEND dataset. The predictiveness curve on the validation data showed similar patterns as the curve on training data, with a predictiveness U of 0.115 (Figure 4).

We sequentially added 2 predictors into the optimal prediction model on the forward selection path (Figure 4). Consistent with the 10-fold cross validation results, the prediction performance on COGEND data decreased as number of predictor was larger than 3. For 5-preidctors model, the predictiveness curve on COGEND data still maintained increasing trend (U=0.112), yet, with a lot of irregularity. For 7-predictors model, we can hardly observed any increasing trend (U=0.0385). As the model complexity is above the optimal threshold, the prediction performance on the testing data decreases due to over-fitting. We plotted value of the predictiveness U and 3 other summary indices (R, AE, TG) as the number of model complexity increased (Figure 5). Predictiveness U showed decreasing trend with some vibration, which reflected the overfitting of the model. Yet, the other 3 indices R, AE and TG show consistently increasing trend, contradicting with the reults in Figure 4.

Discussion

The translation of human genome discoveries into health practice is one of the major challenges in the coming decades. The use of emerging genetic findings from ongoing genome-wide association studies and next-generation sequencing studies for early disease prediction, prevention and pharmacogenetics will advance genome medicine and lead to more effective personalized prevention/treatment strategies[14]. A predicted risk score is helpful for physicians to make personalized clinical decisions. Meanwhile, to evaluate the population impact of a risk model, one needs to consider the distribution of the predictors. Yet, ROC curve, the widely used tool for evaluating prediction model, has recently been criticized for its limitation to reflect population level information[15, 16, 17]. Predictiveness curve, on the other hand, can access the usefulness of a risk prediction model on the population level. In this paper, we proposed an approach to construct predictiveness U and a particial predictiveness U, to assess the predictive value of the model. A global predictiveness U can be calculated to evaluate the prediction performance across the whole population, while a partial predictiveness U is proposed for the clinical interests on a subpopulation (e.g. high risk subpopulation).



Figure 4. Predictiveness curves as model complexities changes

Figure 5. Comparison of Predictiveness U and other summary indices as model complexiity changes



Statistics in Medicine

In this study, we used the risk difference kernel for predictiveness U, and compare our approach with 3 other popular summary indices: R square, Average Entropy and Total Gain. Thorough simulation studies, we showed that R, AE and TG were biased, especially when the heritability is moderate or low, while Predictiveness U obtained robust and accurate estimation. This is partly due to the fact that Predictiveness U can capture the monotonicity of the multi-locus predictiveness curve. Predictiveness curve was first introduced to evaluate the predictive value of a single continuous biomarker with implicit underlying order. Therefore, it's convenient to construct a monotone increasing preidctiveness curve. However, for categorical multi-locus genetic marker, the extension is not straightforward. Since the order of the multi-locus markers depends on the underlying disease model, the predictiveness curve might not monotonically increase in the validation data. Predictiveness U has the capacity to take into account the underlying order of different multilocus genotype and capture the non-monotone information, and thus the advantage over the other summary indices. Although one can use isotonic regression to smooth the curve and force it to be monotone increasing, this additional smoothing procedure is subject to information loss. Nevertheless, to make the comparison more "fair", we performed a simulation by adding the smoothing procedure before calculating summary statistics. Both TG and Predictiveness U had satisfactory results, while R and AE still obtained biased and unstable estimation.

Predictiveness U is built under the framework of U statistic. U statistic, first introduced by Hoeffding[8], is well suitable for nonparametric analysis for high dimension data and have been widely used in genetic association study recently. We here employ this idea in risk prediction study and proposed a predictiveness U to measure the predictiveness of a set of markers. Predictiveness U is unbiased estimator of the kernel $\psi(r_i, r_j)$. Taking the risk difference kernel $\psi(r_i, r_j) = r_i - r_j$, predictiveness U can be interpreted as the expected risk difference across the whole population. If a set of marker can predict the disease status well, it's reasonable to see the risk difference between high risk group and low risk group to be large. Using the standardized form, with scale from 0 to 1, it measures the proportion of risk difference explained by current model. By taking the underlying order of genetic variants taken into account, it can also serve as goodness of fit for the population prediction model.

Although predictiveness U aims at evaluating prediction model at population level, one should always be cautious at how to interpret the result. A high predictiveness U value obtained in one population does not always mean that the model will predict as accurately in another population. Disease-associated genetic markers in different population might be associated with different effect size. Even with the same effect size, the allele or genotype distribution of markers might also be different, so as to infuence the final results. Therefore, one should expect to see different predictiveness U in two heterogeneous populations. Furthermore, a low predictiveness U does not necessarily mean the set of genetic variants is useless. Sometimes, the clinical interest is on the high risk subpopulation. For example, some rare variants might not influence the overall risk in the whole population, but has a large effect on the high risk subpopulation. A partial predictiveness U can reflect the predictiveness of the set of markers on specific risk quantile. Through simulation, we showed that when the rare variants dominated in the disease model, partial predictiveness U is more suitable than predictiveness U on evaluation the prediction model.

The primary study design that predictiveness U can be applied is cohort design, where the population level information is well presented in the study. With the knowledge of disease prevalence, predictiveness U can be easily extended to casecontrol or cross-sectional design. In our real data application, we analyzed FSCD and COGEND case-control dataset by using disease prevalence of 24%. Yet, One should be cautious to infer population predictiveness from case-control studies. The study samples might not be representative for the whole population, due to eligibility criteria and sampling variability. Furthermore, population substructure and correlation between subjects can lead to false positive results. Different studies on the same population might end with different prediction model due to heterogeneity in studies (e.g. different genetic array and quality control process).

In the general formula of predictiveness U, we provided a flexible risk kernel. The choice of the kernel depends on the research questions to be answered. For different diseases, the cost associated with the disease risk can vary. One might want to give a heavy weight on high risk group if it has severe impact. Even for the same disease, the impact can vary according to the characteristics of the population (e.g. medical and economic condition). The information can be incorporated in the risk kernel if needed. In this paper, we attempted to build a risk prediction model for Nicotine Dependence. The primary interest here was to find optimal genetic model that can differentiate the high risk group with low risk group in the population. Therefore, we used risk difference kernel.

We included 37 previously reported SNPs to build the risk prediction model for Nicotine Dependence. To increase the prediction power, we also include several environmental risk factors. The optimal model selected 3 predictors: income, physical trauma and a genetic variant: rs2656073, which attained a moderate predictiveness U value on the testing data. Further investigation of the final model revealed that the genetic variant, compared with the environmental risk factors, only had a small effect on the overall prediction. This is reasonable as for psychiatric diseases individual variants usually have small marginal effects. We can incorporate an ensemble approach to combine multiple small effect genetic variants for future extension. Due to the limitations of available information in the dataset, only 7 environmental risk predictors were included in the analysis. A better predictiveness U model can be attained by including more comprehensive

environmental risk predictors.

Appendix

Appendix A

Let F(g), $F_D(g)$ and $F_{\bar{D}}(g)$ denote the c.d.f of ordered genotype g in the whole population, disease population and nondisease population. We know for ROC curve, $t_g = 1 - F_{\bar{D}}(g)$ and $f(t_g) = 1 - F_D(g)$. Let $F'_D(g)$ and $F'_{\bar{D}}(g)$ be the p.d.f of g in the case and control distribution, we have $f'(t) = \frac{df(t)}{dt} = \frac{F'_D(g)}{F'_D(g)}$. Then each point (q, r(q)) on the predictiveness curve can be written as,

$$q = F(g) = \rho F_D(g) + (1 - \rho) F_{\bar{D}}(g) = \rho (1 - f(t)) + (1 - \rho)(1 - t)$$

r

and

$$\begin{split} (q) &= P(D|g) \\ &= \frac{P(g|D)P(D)}{P(g|D)P(D) + P(g|\bar{D})P(\bar{D})} \\ &= \frac{F'_D(g)\rho}{F'_D(g)\rho + F'_{\bar{D}}(g)(1-\rho)} \\ &= \frac{f'(t)\rho}{f'(t)\rho + (1-\rho)} \end{split}$$

Now we aim to express $U = 2 \int_0^1 \int_0^y (r(y) - r(x)) dx dy$ in the form of $f(\cdot)$. Let $x = \rho(1 - f(t)) + (1 - \rho)(1 - t)$ and $y = \rho(1 - f(s) + (1 - \rho)(1 - s))$. We can calculate dirivarive of x,

$$\frac{dx}{dt} = -(1-\rho) - \rho f'(t)$$

 $x = 1 \Leftrightarrow t = 0,$

Since f(0) = 0 and f(1) = 1, we know

and

$$x = 0 \Leftrightarrow t = 1.$$

Then, we can show

$$\begin{split} U &= 2 \int_0^1 \int_0^y (r(y) - r(x)) dx dy \\ &= 2 \int_1^0 \int_1^s (\frac{f'(s)\rho}{f'(s)\rho + (1-\rho)} - \frac{f'(t)\rho}{f'(t)\rho + (1-\rho)}) [(1-\rho) + \rho f'(t)] [(1-\rho) + \rho f'(s)] dt ds \\ &= 2 \int_0^1 f'(s)\rho \int_s^1 [(1-\rho) + \rho f'(t)] dt ds - 2 \int_0^1 [(1-\rho) + \rho f'(s)] \int_s^1 f'(t)\rho dt ds \\ &= 2 \int_0^1 f'(s)\rho [(1-\rho)(1-s) + \rho(1-f(s))] ds - 2 \int_0^1 [(1-\rho) + \rho f'(s)] (\rho - \rho f(s)) ds \\ &= 2\rho(1-\rho) \int_0^1 [f'(s) - sf'(s) - 1 + f(s)] ds \end{split}$$

Additinally, because $\int_0^1 f'(s)ds = 1$ and $\int_0^1 sf'(s)ds = sf(s)|_0^1 - \int_0^1 f(s)ds$, the above can be further simplified as,

$$U = 2\rho(1-\rho)[2\int_0^1 f(s)ds - 1] = 2\rho(1-\rho)(2AUC_R - 1).$$

Appendix B

We will show the relationship between predictiveness U and AUC_L by first showing the relationship between AUC_R and AUC_L . Using notation in Appendix A and definition of Lorenze curve,

$$\begin{aligned} AUC_L &= \frac{1}{\rho} \int_0^1 \int_0^y r(x) dx dy \\ &= \int_0^1 \int_s^1 f'(t) dt [1 - \rho + \rho f'(s)] ds \\ &= \int_0^1 [1 - f(s)] (1 - \rho + \rho f'(s)) ds \\ &= (1 - \rho) (1 - \int_0^1 f(s) ds) + \rho \int_0^1 f'(s) ds - \rho \int_0^1 f(s) f'(s) ds \\ &= (1 - \rho) (1 - AUC_R) + \rho - \rho \int_0^1 f(s) f'(s) ds \end{aligned}$$

Since $\int_0^1 f(s)f'(s)ds = f(s)f(s)|_0^1 - \int_0^1 f'(s)f(s)ds$, we know $\int_0^1 f(s)f'(s)ds = \frac{1}{2}$. Thus, the above equation can be simplified,

$$AUC_L = (1 - \rho)(1 - AUC_R) + \frac{1}{2}\rho.$$

Since $U = 2\rho(1-\rho)(2AUC_R-1)$, we have

$$U = 2\rho(0.5 - AUC_L).$$

Appendix C

The estimator of predictiveness U can be written as $\hat{U} = 2 \sum_{i>j} \hat{p}_i \hat{p}_j (\hat{r}_i - \hat{r}_j)$, where, we can calculate \hat{p}_i and \hat{r}_i from $\hat{P}(g_i|D)$ and $\hat{P}(g_i|\bar{D})$. Thus we can also write predictiveness U as function of $\hat{P}(g_i|D)$ and $\hat{P}(g_i|\bar{D})$.

$$\begin{split} \hat{U} &= 2\sum_{i=1}^{G_m} \sum_{j=1}^{i} \hat{p}_i \hat{p}_j (\hat{r}_i - \hat{r}_j) \\ &= 2\sum_{i=1}^{G_m} \hat{P}(g_i, D) \sum_{j=1}^{i} \hat{P}(g_i) - 2\sum_{i=1}^{G_m} \hat{P}(g_i) \sum_{j=1}^{i} \hat{P}(g_j, D) \\ &= 2\sum_{i=1}^{G_m} \rho \hat{P}(g_i|D) \sum_{j=1}^{i} [\rho \hat{P}(g_j|D) + (1 - \rho) \hat{P}(g_j|\bar{D})] \\ &- 2\sum_{i=1}^{G_m} [\rho \hat{P}(g_i|D) + (1 - \rho) \hat{P}(g_i|\bar{D})] \sum_{j=1}^{i} \rho \hat{P}(g_j|D) \\ &= 2\rho(1 - \rho) [\sum_{i=1}^{G_m} \hat{P}(g_i|D) \sum_{j=1}^{i} \hat{P}(g_j|\bar{D}) - \sum_{i=1}^{G_m} \hat{P}(g_i|\bar{D}) \sum_{j=1}^{i} \hat{P}(g_j|D)] \end{split}$$

Observing the similarities of the two summations, we can write the above equation as

$$\hat{U} = 2\rho(1-\rho) \left[\sum_{i=1}^{G_m} \sum_{j=1}^{G_m} \hat{P}(g_i|D) \hat{P}(g_j|\bar{D}) (\mathbf{1}_{\{i>j\}} - \mathbf{1}_{\{i$$

where, $\mathbf{1}_{\{\cdot\}}$ is indicator function. Pluging in the estimator $\hat{P}(g_i|D) = \frac{n_{g_i,D}}{n_D}$ and $\hat{P}(g_j|\bar{D}) = \frac{n_{g_i,\bar{D}}}{n_{\bar{D}}}$, we can show that the predictiveness U is a two sample U statistics,

$$\hat{U} = 2\rho(1-\rho)\frac{1}{n_D n_{\bar{D}}} \sum_{i=1}^{G_m} \sum_{j=1}^{G_m} n_{g_i,D} n_{g_j,\bar{D}} (\mathbf{1}_{\{i>j\}} - \mathbf{1}_{\{i
$$= 2\rho(1-\rho)\frac{1}{n_D n_{\bar{D}}} \sum_{s=1}^{n_D} \sum_{t=1}^{n_{\bar{D}}} \phi(g_s, g_t),$$$$

where g_s is the genotype of s-th subject in cases, g_t is the genotype of t-th subject in controls and the kernel $\phi(g_s, g_t)$ is defined as,

$$\phi(g_s, g_t) = \begin{cases} 1, & g_s > g_t \\ 0, & g_s = g_t \\ -1, & g_s < g_t \end{cases}$$

Let $\theta = E(\phi(g_s, g_t))$ and $\theta_U = E(\hat{U}) = 2\rho(1-\rho)\theta$. We can calculate variance of $\hat{U} - \theta_U$,

$$var(\hat{U} - \theta_U) = \frac{4\rho^2(1-\rho)^2}{n_D^2 n_{\bar{D}}^2} var[\sum_{s=1}^{n_{\bar{D}}} \sum_{t=1}^{n_{\bar{D}}} (\phi(g_s, g_t) - \theta)]$$

= $\frac{4\rho^2(1-\rho)^2}{n_D^2 n_{\bar{D}}^2} [n_D n_{\bar{D}} \tau_{1,1} + n_D n_{\bar{D}} (n_{\bar{D}} - 1) \tau_{1,0} + n_D n_{\bar{D}} (n_D - 1) \tau_{0,1}],$

where, $\tau_{1,1} = var(\phi(g_s, g_t)), \tau_{1,0} = cov(\phi(g_s, g_t), \phi(g_s, g_{t'}))$ and $\tau_{0,1} = cov(\phi(g_s, g_t), \phi(g_{s'}, g_t)).$

To obtain the asymptotic distribution of \hat{U} , we can use Hajek projection to project $\hat{U} - \theta_U$ onto the space of the summation forms $\sum_{k=1}^{n_D+n_{\bar{D}}} h(g_k)$, where the CLT can be easily applied. The Hajek projection \tilde{U} of $\hat{U} - \theta_U$ is,

$$\tilde{U} = \sum_{s=1}^{n_{D}} E(\hat{U} - \theta_{U}|g_{s}) + \sum_{t=1}^{n_{\bar{D}}} E(\hat{U} - \theta_{U}|g_{t})$$
$$= \frac{2\rho(1-\rho)}{n_{D}} \sum_{s=1}^{n_{D}} h_{1,0}(g_{s}) + \frac{2\rho(1-\rho)}{n_{\bar{D}}} \sum_{s=1}^{n_{\bar{D}}} h_{0,1}(g_{t}),$$

where $h_{1,0}(g_s) = E(\phi(g_s, g_t) - \theta|g_s)$ and $h_{0,1}(g_t) = E(\phi(g_s, g_t) - \theta|g_t)$. We can then calculate the variance of \tilde{U} ,

$$\begin{aligned} var(\tilde{U}) &= \frac{4\rho^2(1-\rho)^2}{n_D} var(h_{1,0}(g_s)) + \frac{4\rho^2(1-\rho)^2}{n_{\bar{D}}} var(h_{0,1}(g_t)) \\ &= 4\rho^2(1-\rho)^2 [\frac{\tau_{1,0}}{n_D} + \frac{\tau_{0,1}}{n_{\bar{D}}}]. \end{aligned}$$

We can write $\hat{U} - \theta_U$ as a summation of the projection term \tilde{U} and the remainding term \tilde{R} , i.e., $\hat{U} - \theta_U = \tilde{U} + \tilde{R}$. The asymptotic normality of $\hat{U} - \theta_U$ is then established by showing \tilde{U} is asymptotically normal and \tilde{R} is asymptotically negligible. Assuming $n = n_D + n_{\bar{D}}, \frac{n_D}{n} \rightarrow \lambda$, we can apply CLT to \tilde{U} and show that,

$$\sqrt{n}\tilde{U} \rightsquigarrow N(0,4\rho^2(1-\rho)^2[\frac{\tau_{1,0}}{\lambda}+\frac{\tau_{0,1}}{1-\lambda}]).$$

With the fact that $E(\tilde{U}) = 0$, $E(\tilde{R}) = 0$ and $E(\tilde{U}\tilde{R}) = 0$, we know $E(n\tilde{R}^2) = nvar(\hat{U} - \theta) - nvar(\tilde{U}) \rightarrow 0$. Thus, $\sqrt{n\tilde{R}} \xrightarrow{p} 0$. With slusky theorem, we know,

$$\sqrt{n}(\hat{U}-\theta) \rightsquigarrow N(0,4\rho^2(1-\rho)^2[\frac{\tau_{1,0}}{\lambda}+\frac{\tau_{0,1}}{1-\lambda}]).$$

References

- Pepe MS, Feng Z, Huang Y, Longton G, Prentice R, Thompson IM, Zheng Y. Integrating the predictiveness of a marker with its performance as a classifier. *American Journal of Epidemiology* 2008; 167(3):362–368, doi:10.1093/aje/kwm305. URL http://aje.oxfordjournals.org/ content/167/3/362.abstract.
- 2. Huang Y, Pepe MS, Feng Z. Evaluating the predictiveness of a continuous marker. *Biometrics* 2007; **63**(4):1181–1188. URL <GotoISI>://WOS: 000251508300023.
- 3. Huang Y, Pepe MS. Assessing risk prediction models in case-control studies using semiparametric and nonparametric methods. *Statistics in Medicine* 2010; **29**(13):1391–1410. URL <GotoISI>://WOS:000279060000006.
- 4. Mittlbock M, Schemper M. Explained variation for logistic regression. *Statistics in Medicine* 1996; **15**(19):1987–1997. URL <GotoISI>://WOS: A1996VK32500001.
- 5. Cox DR, Wermuth N. A comment on the coefficient of determination for binary responses. *American Statistician* 1992; **46**(1):1–4. URL <GotoISI>: //WOS:A1992HB06200001.
- 6. Shapiro AR. Evaluation of clinical predictions method and initial application. New England Journal of Medicine 1977; 296(26):1509–1514. URL <GotoISI>://WOS:A1977DL21900007.

Statistics in Medicine

- 7. Bura E, Gastwirth JL. The binary regression quantile plot: Assessing the importance of predictors in binary regression visually. *Biometrical Journal* 2001; **43**(1):5–21. URL <GotoISI>://WOS:000167263200002.
- 8. Hoeffding W. A class of statistics with asymptotically normal distribution. *Annals of Mathematical Statistics* 1948; **19**(3):293–325. URL <GotoISI>: //WOS:A1948UM00800001.
- 9. Wei Z, Li MY, Rebbeck T, Li HZ. U-statistics-based tests for multiple genes in genetic association studies. *Annals of Human Genetics* 2008; 72:821–833. URL <GotoISI>://WOS:000259936700012.
- 10. Schaid DJ, McDonnell SK, Hebbring SJ, Cunningham JM, Thibodeau SN. Nonparametric tests of association of multiple genes with human disease. *American Journal of Human Genetics* 2005; **76**(5):780–793. URL <GotoISI>://WOS:000228198300006.
- 11. Lu Q, Elston RC. Using the optimal receiver operating characteristic curve to design a predictive genetic test, exemplified with type 2 diabetes. *The American Journal of Human Genetics* 2008; **82**(3):641–651. URL http://www.sciencedirect.com/science/article/pii/ S0002929708001547.
- 12. Li MD, Cheng R, Ma JZ, Swan GE. A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. *Addiction* 2003; **98**(1):23–31. URL http://dx.doi.org/10.1046/j.1360-0443.2003.00295.x.
- 13. Ye CY, Cui YH, Wei CS, Elston RC, Zhu J, Lu Q. A non-parametric method for building predictive genetic tests on high-dimensional data. *Human Heredity* 2011; **71**(3):161–170. URL <GotoISI>: //WOS:000293078900003.
- 14. Janssens ACJW, Ioannidis JPA, van Duijn CM, Little J, Khoury MJ. Strengthening the reporting of genetic risk prediction studies: the grips statement. Eur J Hum Genet 2011; 19(8):833-836. URL http://dx.doi.org/10.1038/ejhg.2011.25http://www.nature.com/ ejhg/journal/v19/n8/suppinfo/ejhg201125s1.html.
- 15. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. *Circulation* 2007; **115**(7):928–935, doi:10.1161/ circulationaha.106.672402. URL http://circ.ahajournals.org/content/115/7/928.abstract.
- 16. Pepe MS, Feng Z, Gu JW. Comments on 'evaluating the added predictive ability of a new marker: From area under the roc curve to reclassification and beyond' by m. j. pencina et al., statistics in medicine. *Statistics in Medicine* 2008; **27**(2):173–181. URL <GotoISI>://WOS:000253098900002.
- 17. Gail MH, Pfeiffer RM. On criteria for evaluating models of absolute risk. *Biostatistics* 2005; 6(2):227-239, doi:10.1093/biostatistics/kxi005. URL http://biostatistics.oxfordjournals.org/content/6/2/227.abstract.